Unified Network for Integrated Fluid Collection at Yale

UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Molecular Residual Disease Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Smilow Cancer Hospital

New Haven, Connecticut, 06519, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and/or significant family history of malignancy).
Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY.
If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence.

Exclusion criteria

Inability to provide informed consent.
Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).

Treatment and study plan

Primary outcomes

Collection and annotation of biospecimens

Time frame: Through study completion, up to 5 years

Facilitate and streamline the collection, banking, and clinical annotation of liquid biopsy biospecimens (peripheral blood collected in Streck Cell-Free DNA BCT® tubes or blood spots) - and, optionally, corresponding archival tumor specimens - for cancer research studies across Yale Cancer Center and the Smilow Cancer Hospital network.

Secondary outcomes

Establish a repository

Time frame: Through study completion, up to 5 years

Establish a repository of clinically annotated liquid biopsy biospecimens (and optional archival tumor specimens) for current and future research.
Collection of blood for additional methods

Time frame: Through study completion, up to 5 years

Facilitate the collection of blood for additional methods of scientific analysis in parallel with cfNA analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Mitchell Elliott, MD

CONTACT

[email protected]

475-375-7981

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Acronym: UNIFY

Important dates

Study start: 2026
Primary completion: 2031
Study completion: 2031
First posted: Jul 8, 2026
Registry last updated: Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting